Randomized phase 3 trials report maintenance therapy outcomes for subcutaneous infliximab in inflammatory bowel disease, indicating a unique exposure profile.
CT-P13 subcutaneous (SC), an SC formulation of the intravenous (IV) infliximab biosimilar CT-P13 IV, creates a unique exposure profile. The LIBERTY studies aimed to demonstrate superiority of CT-P13 SC vs placebo as maintenance therapy in patients with Crohn's disease (CD) and ulcerative colitis (UC).
No takes yet. Share an insight, caveat, or question.
Hanauer et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: